Clinical Cancer Research, Vol 3, Issue 9 1501-1505, Copyright © 1997 by American Association for Cancer Research

ARTICLES

A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix

AP Kudelka, T Levy, CF Verschraegen, CL Edwards, S Piamsomboon, W Termrungruanglert, RS Freedman, AL Kaplan, DG Kieback, CA Meyers, KA Jaeckle, E Loyer, M Steger, R Mante, G Mavligit, A Killian, RA Tang, JU Gutterman and JJ Kavanagh
Departments of Clinical Investigations, Gynecologic Oncology, Clinical Immunology and Biological Therapy, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030-4059, USA.

A Phase I study of the novel angiogenesis inhibitor TNP-470 was performed. Patients with inoperable recurring or metastatic squamous cell cancer of the cervix with evaluable disease, no coagulopathy, and adequate renal, hepatic, and hematological function were eligible. One course of treatment consisted of an i.v. infusion of TNP-470 over 60 min every other day for 28 days, followed by a 14-day rest period. The starting dose was 9.3 mg/m2. Eighteen evaluable patients were treated, with a median age of 48 years (range 27-55) and performance status Zubrod 1 (range 0-2). Grade 3 neurotoxicities consisting of weakness, nystagmus, diplopia, and ataxia were encountered in two patients receiving the 71.2 mg/m2 dose. An intermediate dose level of 60 mg/m2 was evaluated and found to be well tolerated by three patients. Only one patient experienced grade 3 nausea on the 60 mg/m2 dose level. No myelosuppression, retinal hemorrhage, weight loss, or significant alopecia were observed. One patient had a complete response, which continues for 26 months, and three patients with initially progressive disease stage had stable disease for 5, 7.7, and 19+ months. Other Phase I studies, including over 200 patients, were performed concurrently with this study. Based on this experience, the dose of TNP-470 recommended for further studies is 60 mg/m2 as a 60-min i.v. infusion every Monday, Wednesday, and Friday. Neurotoxicity was dose limiting, but appears to be reversible. Otherwise, the treatment was well tolerated. The drug may be active in squamous cell cancer of the cervix. Further studies of TNP-470 in squamous cell cancer of the cervix are warranted.

This article has been cited by other articles:

				D. Kass, R. S. Bridges, A. Borczuk, and S. Greenberg Methionine Aminopeptidase-2 as a Selective Target of Myofibroblasts in Pulmonary Fibrosis Am. J. Respir. Cell Mol. Biol., August 1, 2007; 37(2): 193 - 201. [Abstract] [Full Text] [PDF]

				H. Nakagami, N. Nakagawa, Y. Takeya, K. Kashiwagi, C. Ishida, S.-i. Hayashi, M. Aoki, K. Matsumoto, T. Nakamura, T. Ogihara, et al. Model of Vasculogenesis from Embryonic Stem Cells for Vascular Research and Regenerative Medicine Hypertension, July 1, 2006; 48(1): 112 - 119. [Abstract] [Full Text] [PDF]

				X. Chang, J. C. Tou, C. Hong, H.-A. Kim, J. E. Riby, G. L. Firestone, and L. F. Bjeldanes 3,3'-Diindolylmethane inhibits angiogenesis and the growth of transplantable human breast carcinoma in athymic mice Carcinogenesis, April 1, 2005; 26(4): 771 - 778. [Abstract] [Full Text] [PDF]

				M. J. Morowitz, R. Barr, Q. Wang, R. King, N. Rhodin, B. Pawel, H. Zhao, S. A. Erickson, G. S. Sheppard, J. Wang, et al. Methionine Aminopeptidase 2 Inhibition Is an Effective Treatment Strategy for Neuroblastoma in Preclinical Models Clin. Cancer Res., April 1, 2005; 11(7): 2680 - 2685. [Abstract] [Full Text] [PDF]

				S. G. Bernier, D. D. Lazarus, E. Clark, B. Doyle, M. T. Labenski, C. D. Thompson, W. F. Westlin, and G. Hannig A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis PNAS, July 20, 2004; 101(29): 10768 - 10773. [Abstract] [Full Text] [PDF]

				C. M. Brdlik and C. M. Crews A Single Amino Acid Residue Defines the Difference in Ovalicin Sensitivity between Type I and II Methionine Aminopeptidases J. Biol. Chem., March 5, 2004; 279(10): 9475 - 9480. [Abstract] [Full Text] [PDF]

				J. Wang, G. S. Sheppard, P. Lou, M. Kawai, N. BaMaung, S. A. Erickson, L. Tucker-Garcia, C. Park, J. Bouska, Y.-C. Wang, et al. Tumor Suppression by a Rationally Designed Reversible Inhibitor of Methionine Aminopeptidase-2 Cancer Res., November 15, 2003; 63(22): 7861 - 7869. [Abstract] [Full Text] [PDF]

				V. Chhokar and A. L. Tucker Angiogenesis: Basic Mechanisms and Clinical Applications Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2003; 7(3): 253 - 280. [Abstract] [PDF]

				B. B.Y. Ma, R. G. Bristow, J. Kim, and L. L. Siu Combined-Modality Treatment of Solid Tumors Using Radiotherapy and Molecular Targeted Agents J. Clin. Oncol., July 15, 2003; 21(14): 2760 - 2776. [Abstract] [Full Text] [PDF]

				R. S. Herbst, T. L. Madden, H. T. Tran, G. R. Blumenschein Jr, C. A. Meyers, L. F. Seabrooke, F. R. Khuri, V. K. Puduvalli, V. Allgood, H. A. Fritsche Jr, et al. Safety and Pharmacokinetic Effects of TNP-470, an Angiogenesis Inhibitor, Combined With Paclitaxel in Patients With Solid Tumors: Evidence for Activity in Non-Small-Cell Lung Cancer J. Clin. Oncol., November 15, 2002; 20(22): 4440 - 4447. [Abstract] [Full Text] [PDF]

				S. Shusterman, S. A. Grupp, R. Barr, D. Carpentieri, H. Zhao, and J. M. Maris The Angiogenesis Inhibitor TNP-470 Effectively Inhibits Human Neuroblastoma Xenograft Growth, Especially in the Setting of Subclinical Disease Clin. Cancer Res., April 1, 2001; 7(4): 977 - 984. [Abstract] [Full Text]

				W. M. Stadler, T. Kuzel, C. Shapiro, J. Sosman, J. Clark, and N. J. Vogelzang Multi-Institutional Study of the Angiogenesis Inhibitor TNP-470 in Metastatic Renal Carcinoma J. Clin. Oncol., August 1, 1999; 17(8): 2541 - 2541. [Abstract] [Full Text] [PDF]

				A. P. Kudelka, C. F. Verschraegen, and E. Loyer Complete Remission of Metastatic Cervical Cancer with the Angiogenesis Inhibitor TNP-470 N. Engl. J. Med., April 2, 1998; 338(14): 991 - 992. [Full Text]